Class summary at a glance.

Every drug in the Loop Diuretic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $448.1Mcombined across class
Total Rx claims: 43.5M12.9M unique beneficiaries
Generic mfrs (active): 53across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Furosemide

Brand: LASIX ONYU · 35.2M Part D claims (CY24) · 10.5M beneficiaries · First FDA approval: 1978-04-24

21 generic mfrs 0 plans require PA Active FDA shortage

Low NADAC$0.027

→

Avg plan cost$0.204

Part D spend $231.6M 8× spread, current vs floor

Class share

52%

of class CY24 spend

View profile →

Bumetanide

Brand: Bumex · 3.7M Part D claims (CY24) · 1.0M beneficiaries · First FDA approval: 1983-02-28

19 generic mfrs 2 plans require PA Active FDA shortage

Low NADAC$0.115

→

Avg plan cost$0.143

Part D spend $116.6M 1× spread, current vs floor

Class share

26%

of class CY24 spend

View profile →

Torsemide

Brand: SOAANZ · 4.6M Part D claims (CY24) · 1.4M beneficiaries · First FDA approval: 2004-06-01

6 generic mfrs 0 plans require PA

Low NADAC$0.063

→

Avg plan cost$0.097

Part D spend $90.6M 2× spread, current vs floor

Class share

20%

of class CY24 spend

View profile →

Ethacrynic Acid

Brand: EDECRIN · 23K Part D claims (CY24) · 7K beneficiaries · First FDA approval: 1967-01-10

7 generic mfrs 2 plans require PA

Low NADAC$0.816

→

Avg plan cost$0.816

Part D spend $9.3M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Furosemide Injection

Brand: FUROSCIX · — Part D claims (CY24) · First FDA approval: 2022-11-14

Brand-only (no generics) 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.